Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

General Motors

Finding long-term stocks isn't always easy. Avoiding meme stock mania, FOMO, and value traps is difficult in any economy but particularly troublesome today.

3 Evergreen Stocks for Long-term Wealth Generation

AbbVie

Amcor Plc

Franklin Resources

Cincinnati Financial

Chevron

Essex Property Trust

Federal Realty Investment Trust

NextEra Energy

Realty Income Corp

Target

T. Rowe Price Group

Walgreens

Exxon Mobil

"Dividend Aristocrats in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "-- Kiplinger.com/Investing. 66 Aristocrats, screened as of November 6, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 22.29%-34.44% topped-by O & WBA.

4 Dividend Aristocrats Signal Buys In November As 6 Await

Constellation Energy Corp

JPMorgan Chase & Co

For many years through 2022, it was becoming more difficult for active fund managers to make the case for their services, when broad index funds, with lower fees, were performing so well. But the tech-driven market decline for 2022 might have made some investors think again about different investment styles for the long term.

Three value stock picks from a veteran manager with a good performance record

GE HealthCare Technologies Inc

Johnson & Johnson

Artificial intelligence is expected to transform the healthcare sector radically over the next 10 years. These three companies are leading the charge to implement AI into their product offerings and day-to-day operations.

3 Brilliant Artificial Intelligence Stocks to Buy and Hold Forever

Clorox

The Market believes the Fed may pause rate hikes and soon pivot, leading to increased demand for 10-year Treasury bonds. Long-duration US Treasuries may not be a good investment unless they yield more than 600 basis points over the S&P 500 dividend. Investing in large dividend-paying stocks with yields over 3% may be a better alternative to buying long duration government debt.

5 Kings And Aristocrats Selling At Decade High Dividend Yields

DUBLIN , Nov. 7, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2024 on Tuesday, November 21, 2023. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its second quarter of fiscal year 2024

Albemarle

Community Bank System

Altria

National Fuel Gas

Polaris

Essential Utilities

Economists say the recession is canceled; the bond market is 98% sure it's still coming. The bond market is likely right, BUT history is very clear, the time to buy wonderful companies at wonderful prices is now. Warren Buffett-style aristocrat bargains are blue-chip quality aristocrats trading at anti-bubble "fat pitch" valuations.

10 Buffett-Style Dividend Aristocrat Bargains You Don't Want To Miss

CRISPR Therapeutics

One of these players is approaching a big milestone: potential product approval. The other two companies recently made moves to transform their businesses, and this may spur a new chapter of growth.

3 Healthcare Stocks to Buy Hand Over Fist in November

Abbott Labs

Archer-Daniels-Midland Company

Automatic Data Processing

Aflac

A. O. Smith

Air Products and Chemicals

Atmos Energy

Becton, Dickinson and Co.

Brown & Brown

Cardinal Health

Caterpillar

Chubb

Colgate-Palmolive

Cintas Corp

Dover

Ecolab

Con Ed

Emerson Electric

Expeditors International of Washington

General Dynamics

Genuine Parts

W.W. Grainger

Hormel Foods

Illinois Tool Works

Kimberly-Clark

Coca-Cola

New Linde PLC

Lowe's

McDonald's

McCormick

Nordson

Nucor

PepsiCo

Procter & Gamble

Pentair

PPG Industries

Roper Technologies

Sherwin-Williams

S&P Global

Stanley Black & Decker

Sysco

V.F.

Walmart

West Pharmaceutical Services

The highest yield isn't everything when it comes to finding the best dividend stocks. Income investors know there's no substitute for regular dividend increases over the long haul.

67 Best Dividend Stocks for Dependable Dividend Growth

AT&T

Because of their underappreciated value factor, most dividend stocks tend to be top performers over long holding periods. AT&T and Medtronic offer investors high yields and extremely attractive valuations.

2 Incredibly Cheap Dividend Stocks to Buy Hand Over Fist Ahead of 2024

News for Medtronic Stock (MDT)